Study With Various Immunotherapy Treatments in Participants With Lung Cancer
This research study is for people with advanced non-small cell lung cancer. It's testing different combinations of new medicines, including ones called Domvanalimab, Quemliclustat, and Zimberelimab, sometimes with existing treatments like Docetaxel. The main aim is to find out how effective these new combinations are at shrinking or controlling the cancer (this is called the 'objective response rate'). Researchers also want to understand how safe these new treatments are and what side effects they might cause. By looking at these things, the study hopes to discover better treatment options for this kind of cancer.
De un vistazo
¿De qué trata este estudio?
This study is exploring potential new ways to treat a type of lung cancer called advanced non-small cell lung cancer. In this study, doctors are testing different combinations of new medications, often referred to as 'immunotherapy'. Immunotherapy works by helping your body's own immune system fight the cancer cells.
The study has a few main goals. Firstly, it wants to see how well these new combinations shrink the cancer or stop it from growing. This is important for understanding if the treatments are effective. Secondly, the researchers are carefully checking the safety of these new medicine combinations. They want to know what possible side effects might occur and how well people tolerate the treatments. This will help them understand if the treatments are not only effective but also manageable for patients.
By carefully studying these new combinations, the researchers hope to find more effective and safer treatment options for people living with advanced non-small cell lung cancer. This work is a step towards improving care and offering more choices for patients in the future.
Puntos clave
- This study evaluates new immunotherapy combinations for advanced lung cancer.
- It aims to find effective and safe new treatment options.
- Participation involves regular medical check-ups and monitoring.
- You might receive new treatments not yet widely available.
- Your health and safety are a top priority throughout the study.
¿Quién puede ser elegible?
To join this study, you would need to have advanced non-small cell lung cancer that has spread. Doctors would check that your general health is good enough for you to take part, and that the cancer can be measured. You would also need to be willing to provide a small sample of your tumour tissue for testing.
There are also some reasons why you might not be able to join. For example, if you have other serious health problems that the doctors think would make the study medicines unsafe for you. You also couldn't have had certain live vaccinations recently, or be taking high doses of steroid medications or other medicines that suppress your immune system just before starting the study. Certain autoimmune diseases might also prevent you from joining.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Do you have advanced non-small cell lung cancer that has spread?
- Is your general health good enough for you to take part?
- Do you have cancer that doctors can measure?
- Are you willing to provide a tumour tissue sample?
- Have you avoided live vaccines in the last 28 days?
- Are you taking any high-dose steroid or immune-suppressing medicines?
¿En qué consiste la participación?
If you decide to take part in this study, you would receive one of the new medicine combinations. You would have regular visits to the clinic for check-ups, where doctors would monitor your health and how the treatment is affecting you. This would include tests like blood samples and scans to see how your cancer is responding. The doctors and nurses would also ask about any side effects you might be experiencing. The exact number of visits and tests, and the total length of time you'd be in the study, would be explained to you in detail.
Riesgos y beneficios potenciales
Ubicaciones (53)
- University of Alabama at Birmingham (UAB)Código postal verificadoBirmingham, United States
- University of California San Diego (UCSD)Código postal verificadoLa Jolla, Estados Unidos
- Memorial Cancer Institute at Memorial Regional HospitalCódigo postal verificadoHollywood, Estados Unidos
- Hematology Oncology Associates Of The Treasure CoastCódigo postal verificadoPort Saint Lucie, United States
- Florida Cancer Specialists (Administration and Drug Shipment)Código postal verificadoThe Villages, United States
- Northwestern Memorial HospitalCódigo postal verificadoChicago, Estados Unidos
- Ochsner Clinic FoundationCódigo postal verificadoJefferson, United States
- Henry Ford HospitalCódigo postal verificadoDetroit, Estados Unidos
- Virginia Cancer Specialists, PCCódigo postal verificadoFairfax, United States
- Medical Oncology Associated, PS (dba Summit Cancer Centers)Código postal verificadoSpokane, United States
- The Border Cancer HospitalCódigo postal verificadoAlbury, Australia
- Pindara Private HospitalCódigo postal verificadoBenowa, Australia
Preguntas comunes
What is non-small cell lung cancer?
It's the most common type of lung cancer, and 'advanced' means it has spread to other parts of the body.
¿Qué es la inmunoterapia?
Immunotherapy helps your body's own defence system fight cancer cells by boosting its ability to recognise and attack them.
What does a 'combination therapy' mean?
It means you'll be given more than one medicine at the same time, as they might work better together than alone.
Will I know which treatment I'm getting?
The study design details this. You will be fully informed before deciding to take part.
What happens after the study ends?
This will be discussed with you, but your care will always be continued by your regular medical team.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.